NO327285B1 - Farmasoytisk sammensetning med langvarig frigivelse og anvendelse derav - Google Patents

Farmasoytisk sammensetning med langvarig frigivelse og anvendelse derav Download PDF

Info

Publication number: NO327285B1
Authority: NO; Norway
Prior art keywords: weight; pharmaceutical composition; average molecular; number average; molecular weight
Prior art date: 1998-10-14

Application number

NO20011695A

Other languages

English (en)

Norwegian (no)

Other versions

NO20011695L (no

NO20011695D0 (no

Inventor

Rajen Shah

Arun P Patel

Roy T Sandry

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-10-14

Filing date

2001-04-04

Publication date

2009-06-02

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22627919&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO327285(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-04-04 Application filed by Novartis Ag filed Critical Novartis Ag

2001-04-04 Publication of NO20011695D0 publication Critical patent/NO20011695D0/no

2001-05-30 Publication of NO20011695L publication Critical patent/NO20011695L/no

2009-06-02 Publication of NO327285B1 publication Critical patent/NO327285B1/no

Links

239000008194 pharmaceutical composition Substances 0.000 title claims description 30
230000002035 prolonged effect Effects 0.000 title description 7
239000000203 mixture Substances 0.000 claims description 54
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 36
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 36
229920001477 hydrophilic polymer Polymers 0.000 claims description 21
229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 18
235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 18
ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 claims description 16
-1 poly(ethylene oxide) Polymers 0.000 claims description 14
239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 13
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 13
229960003765 fluvastatin Drugs 0.000 claims description 11
229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 10
239000001863 hydroxypropyl cellulose Substances 0.000 claims description 10
229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 8
235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 8
239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 6
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 6
150000003839 salts Chemical class 0.000 claims description 6
239000003814 drug Substances 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims description 3
239000013543 active substance Substances 0.000 description 34
238000004090 dissolution Methods 0.000 description 19
239000002552 dosage form Substances 0.000 description 17
230000000052 comparative effect Effects 0.000 description 14
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
238000003756 stirring Methods 0.000 description 11
239000011159 matrix material Substances 0.000 description 9
238000000034 method Methods 0.000 description 9
230000002028 premature Effects 0.000 description 9
230000037406 food intake Effects 0.000 description 7
239000008363 phosphate buffer Substances 0.000 description 7
239000000499 gel Substances 0.000 description 6
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
229960000868 fluvastatin sodium Drugs 0.000 description 5
229920000642 polymer Polymers 0.000 description 5
239000000243 solution Substances 0.000 description 5
238000013268 sustained release Methods 0.000 description 5
239000012730 sustained-release form Substances 0.000 description 5
229920003091 Methocel™ Polymers 0.000 description 4
239000012153 distilled water Substances 0.000 description 4
210000000056 organ Anatomy 0.000 description 4
235000015497 potassium bicarbonate Nutrition 0.000 description 4
229910000028 potassium bicarbonate Inorganic materials 0.000 description 4
239000011736 potassium bicarbonate Substances 0.000 description 4
TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 3
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
239000008351 acetate buffer Substances 0.000 description 3
238000005469 granulation Methods 0.000 description 3
230000003179 granulation Effects 0.000 description 3
239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 3
239000004615 ingredient Substances 0.000 description 3
235000019359 magnesium stearate Nutrition 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
229920000168 Microcrystalline cellulose Polymers 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
239000012738 dissolution medium Substances 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
238000004880 explosion Methods 0.000 description 2
238000001879 gelation Methods 0.000 description 2
239000008187 granular material Substances 0.000 description 2
239000012729 immediate-release (IR) formulation Substances 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
239000000463 material Substances 0.000 description 2
235000019813 microcrystalline cellulose Nutrition 0.000 description 2
229940016286 microcrystalline cellulose Drugs 0.000 description 2
239000008108 microcrystalline cellulose Substances 0.000 description 2
229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
239000004033 plastic Substances 0.000 description 2
229940069328 povidone Drugs 0.000 description 2
239000008213 purified water Substances 0.000 description 2
BBMHARZCALWXSL-UHFFFAOYSA-M sodium dihydrogenphosphate monohydrate Chemical compound O.[Na+].OP(O)([O-])=O BBMHARZCALWXSL-UHFFFAOYSA-M 0.000 description 2
239000007921 spray Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
102220487426 Actin-related protein 2/3 complex subunit 3_K15M_mutation Human genes 0.000 description 1
229920002785 Croscarmellose sodium Polymers 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
229920000881 Modified starch Polymers 0.000 description 1
PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
230000000181 anti-adherent effect Effects 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
229940082483 carnauba wax Drugs 0.000 description 1
239000004203 carnauba wax Substances 0.000 description 1
235000013869 carnauba wax Nutrition 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
239000003086 colorant Substances 0.000 description 1
229960005168 croscarmellose Drugs 0.000 description 1
229960000913 crospovidone Drugs 0.000 description 1
239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
230000000694 effects Effects 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
239000012456 homogeneous solution Substances 0.000 description 1
239000008172 hydrogenated vegetable oil Substances 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
229960004844 lovastatin Drugs 0.000 description 1
PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229940094025 potassium bicarbonate Drugs 0.000 description 1
238000012545 processing Methods 0.000 description 1
229920003109 sodium starch glycolate Polymers 0.000 description 1
229940079832 sodium starch glycolate Drugs 0.000 description 1
239000008109 sodium starch glycolate Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
238000011282 treatment Methods 0.000 description 1
230000004584 weight gain Effects 0.000 description 1
235000019786 weight gain Nutrition 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Hematology (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Obesity (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Pulmonology (AREA)
Epidemiology (AREA)
Anesthesiology (AREA)
Psychiatry (AREA)
Vascular Medicine (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

NO20011695A 1998-10-14 2001-04-04 Farmasoytisk sammensetning med langvarig frigivelse og anvendelse derav NO327285B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US17249198A	1998-10-14	1998-10-14
PCT/EP1999/007627 WO2000021525A2 (en)	1998-10-14	1999-10-12	Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent

Publications (3)

Publication Number	Publication Date
NO20011695D0 NO20011695D0 (no)	2001-04-04
NO20011695L NO20011695L (no)	2001-05-30
NO327285B1 true NO327285B1 (no)	2009-06-02

Family

ID=22627919

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20011695A NO327285B1 (no)	1998-10-14	2001-04-04	Farmasoytisk sammensetning med langvarig frigivelse og anvendelse derav

Country Status (30)

Country	Link
EP (1)	EP1121116B1 (de)
JP (2)	JP2002527388A (de)
KR (1)	KR100517090B1 (de)
CN (1)	CN1196481C (de)
AR (2)	AR020780A1 (de)
AT (1)	ATE382345T1 (de)
AU (1)	AU765475B2 (de)
BR (1)	BR9911648A (de)
CA (1)	CA2346868C (de)
CO (1)	CO5140079A1 (de)
CY (1)	CY1107874T1 (de)
DE (1)	DE69937891T2 (de)
DK (1)	DK1121116T3 (de)
ES (1)	ES2297936T3 (de)
HK (1)	HK1040920B (de)
HU (1)	HUP0104268A3 (de)
ID (1)	ID29350A (de)
IL (2)	IL142375A0 (de)
MY (1)	MY121105A (de)
NO (1)	NO327285B1 (de)
NZ (1)	NZ511010A (de)
PE (1)	PE20001110A1 (de)
PL (1)	PL198850B1 (de)
PT (1)	PT1121116E (de)
RU (1)	RU2259826C2 (de)
SK (2)	SK286595B6 (de)
TR (1)	TR200101088T2 (de)
TW (1)	TW577738B (de)
WO (1)	WO2000021525A2 (de)
ZA (1)	ZA200103001B (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6569461B1 (en)	1999-03-08	2003-05-27	Merck & Co., Inc.	Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors
US6242003B1 (en) *	2000-04-13	2001-06-05	Novartis Ag	Organic compounds
ATE418979T2 (de)	2000-06-09	2009-01-15	Lek Pharmaceuticals	Stabilisiertes arzneimittel und arzneizubereitung
ES2284709T3 (es) *	2000-09-29	2007-11-16	Solvay Pharmaceuticals B.V.	Formulacion farmaceutica de liberacion sostenida independiente de la fuerza ionica.
US20060127474A1 (en)	2001-04-11	2006-06-15	Oskar Kalb	Pharmaceutical compositions comprising fluvastatin
WO2004024184A1 (ja) *	2002-09-11	2004-03-25	Takeda Pharmaceutical Company Limited	徐放性製剤
JP2007523664A (ja)	2003-04-23	2007-08-23	フェリングベスローテンフェンノートシャップ	医薬組成物用サシェ
US8987322B2 (en)	2003-11-04	2015-03-24	Circ Pharma Research And Development Limited	Pharmaceutical formulations for carrier-mediated transport statins and uses thereof
DE102004062475A1 (de) *	2004-12-24	2006-07-06	Bayer Healthcare Ag	Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
KR100582347B1 (ko) *	2004-12-30	2006-05-22	한미약품 주식회사	3-하이드록시-3-메틸글루타릴 조효소 ａ 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법
CA2615941A1 (en) *	2005-08-05	2007-02-15	Orbus Pharma Inc.	Stabilized extended release pharmeceutical compositions comprising an hmg-coa reductase inhibitor
BRPI0708191A2 (pt) *	2006-02-24	2012-05-29	Teva Pharma	" composições farmacêuticas de fluvastatina sódica "
RU2342144C1 (ru) *	2007-04-05	2008-12-27	Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН")	Фармацевтический состав, обладающий противосудорожным и психотропным действием
RU2356532C2 (ru) *	2007-06-01	2009-05-27	Открытое Акционерное Общество "Отечественные Лекарства"	Фармацевтическая композиция проксодолола с контролируемым высвобождением
CN102805739B (zh) *	2012-04-10	2013-08-14	宋芸	氟伐他汀钠缓释包衣滴丸及其制备方法
EP2943186A1 (de) *	2013-01-09	2015-11-18	Edgemont Pharmaceuticals LLC	Lorazepamformulierungen mit kontrollierter freisetzung
CN106344535B (zh) *	2016-08-29	2019-09-20	济南康和医药科技有限公司	一种氟伐他汀钠微孔渗透泵控释片及其制备方法
CN118593482A (zh)	2017-12-05	2024-09-06	赛诺维信制药公司	非外消旋混合物及其用途
WO2019113084A1 (en)	2017-12-05	2019-06-13	Sunovion Pharmaceuticals Inc.	Crystal forms and production methods thereof
US11802103B2 (en)	2018-09-25	2023-10-31	Ponce De Leon Health Designated Activity Company	Process of making calcium alpha-ketoglutarate
MX2021014774A (es)	2019-06-04	2022-02-03	Sunovion Pharmaceuticals Inc	Formulaciones de liberacion modificada y usos de las mismas.
EP3980001B1 (de) *	2019-06-10	2025-08-27	Ponce de Leon Health Designated Activity Company	Zusammensetzungen von alpha-ketoglutarat verzögerter freisetzung

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4915954A (en) *	1987-09-03	1990-04-10	Alza Corporation	Dosage form for delivering a drug at two different rates
CA2045428A1 (en) *	1990-06-26	1991-12-27	Alfred W. Alberts	Method for enhancing the lowering of plasma cholesterol levels
ZA959221B (en) *	1994-11-02	1997-04-30	Janssen Pharmaceutica Nv	Cisapride extended release
US5798375A (en) *	1995-07-03	1998-08-25	Sankyo Company, Limited	Treatment of arteriosclerosis and xanthoma
GB9523752D0 (en) *	1995-11-21	1996-01-24	Pfizer Ltd	Pharmaceutical formulations
DE69625046T2 (de) *	1995-12-22	2003-04-10	Kowa Co., Ltd.	Pharmazeutische zusammensetzung stabilisiert mit einem basischen medium
SE9603667D0 (sv) *	1996-10-08	1996-10-08	Astra Ab	Pharmaceutical compositions

1999
- 1999-10-05 CO CO99062951A patent/CO5140079A1/es unknown
- 1999-10-12 PT PT99947489T patent/PT1121116E/pt unknown
- 1999-10-12 CN CNB998120812A patent/CN1196481C/zh not_active Expired - Lifetime
- 1999-10-12 AU AU60909/99A patent/AU765475B2/en not_active Expired
- 1999-10-12 EP EP99947489A patent/EP1121116B1/de not_active Revoked
- 1999-10-12 PE PE1999001027A patent/PE20001110A1/es not_active IP Right Cessation
- 1999-10-12 WO PCT/EP1999/007627 patent/WO2000021525A2/en not_active Ceased
- 1999-10-12 HK HK02102698.9A patent/HK1040920B/zh not_active IP Right Cessation
- 1999-10-12 CA CA002346868A patent/CA2346868C/en not_active Expired - Lifetime
- 1999-10-12 IL IL14237599A patent/IL142375A0/xx unknown
- 1999-10-12 DE DE69937891T patent/DE69937891T2/de not_active Expired - Lifetime
- 1999-10-12 BR BR9911648-0A patent/BR9911648A/pt not_active Application Discontinuation
- 1999-10-12 TR TR2001/01088T patent/TR200101088T2/xx unknown
- 1999-10-12 ES ES99947489T patent/ES2297936T3/es not_active Expired - Lifetime
- 1999-10-12 RU RU2001111882/15A patent/RU2259826C2/ru active
- 1999-10-12 AR ARP990105146A patent/AR020780A1/es not_active Application Discontinuation
- 1999-10-12 HU HU0104268A patent/HUP0104268A3/hu not_active Application Discontinuation
- 1999-10-12 PL PL348109A patent/PL198850B1/pl unknown
- 1999-10-12 SK SK509-2001A patent/SK286595B6/sk not_active IP Right Cessation
- 1999-10-12 NZ NZ511010A patent/NZ511010A/en not_active IP Right Cessation
- 1999-10-12 SK SK5054-2008A patent/SK286596B6/sk not_active IP Right Cessation
- 1999-10-12 DK DK99947489T patent/DK1121116T3/da active
- 1999-10-12 AT AT99947489T patent/ATE382345T1/de active
- 1999-10-12 ID IDW20010807A patent/ID29350A/id unknown
- 1999-10-12 JP JP2000575501A patent/JP2002527388A/ja active Pending
- 1999-10-12 KR KR10-2001-7004708A patent/KR100517090B1/ko not_active Expired - Lifetime
- 1999-10-13 MY MYPI99004430A patent/MY121105A/en unknown
- 1999-10-14 TW TW088117692A patent/TW577738B/zh not_active IP Right Cessation
2001
- 2001-04-02 IL IL142375A patent/IL142375A/en not_active IP Right Cessation
- 2001-04-04 NO NO20011695A patent/NO327285B1/no not_active IP Right Cessation
- 2001-04-11 ZA ZA200103001A patent/ZA200103001B/en unknown
2006
- 2006-08-14 JP JP2006221194A patent/JP4938383B2/ja not_active Expired - Fee Related
2008
- 2008-02-04 CY CY20081100134T patent/CY1107874T1/el unknown
- 2008-11-11 AR ARP080104921A patent/AR069281A2/es not_active Application Discontinuation

Also Published As

Publication number	Publication date
DE69937891T2 (de)	2008-12-11
CA2346868C (en)	2008-09-09
NZ511010A (en)	2003-10-31
SK286595B6 (sk)	2009-01-07
EP1121116B1 (de)	2008-01-02
HUP0104268A3 (en)	2002-06-28
ATE382345T1 (de)	2008-01-15
ZA200103001B (en)	2002-07-11
CA2346868A1 (en)	2000-04-20
JP4938383B2 (ja)	2012-05-23
NO20011695L (no)	2001-05-30
CO5140079A1 (es)	2002-03-22
RU2259826C2 (ru)	2005-09-10
PE20001110A1 (es)	2000-11-01
TR200101088T2 (tr)	2001-10-22
JP2006298945A (ja)	2006-11-02
ES2297936T3 (es)	2008-05-01
AR069281A2 (es)	2010-01-13
AU6090999A (en)	2000-05-01
CN1196481C (zh)	2005-04-13
HK1040920A1 (en)	2002-06-28
AU765475B2 (en)	2003-09-18
HK1040920B (zh)	2005-07-29
ID29350A (id)	2001-08-23
EP1121116A2 (de)	2001-08-08
KR20010080156A (ko)	2001-08-22
IL142375A (en)	2012-01-31
JP2002527388A (ja)	2002-08-27
CY1107874T1 (el)	2013-06-19
TW577738B (en)	2004-03-01
PT1121116E (pt)	2008-03-12
BR9911648A (pt)	2001-03-20
SK286596B6 (sk)	2009-01-07
CN1328454A (zh)	2001-12-26
HUP0104268A2 (hu)	2002-04-29
KR100517090B1 (ko)	2005-09-27
PL348109A1 (en)	2002-05-06
PL198850B1 (pl)	2008-07-31
DK1121116T3 (da)	2008-05-13
MY121105A (en)	2005-12-30
SK5092001A3 (en)	2001-09-11
DE69937891D1 (de)	2008-02-14
IL142375A0 (en)	2002-03-10
WO2000021525A2 (en)	2000-04-20
NO20011695D0 (no)	2001-04-04
AR020780A1 (es)	2002-05-29
WO2000021525A3 (en)	2000-08-10

Legal Events

Date	Code	Title	Description
2019-11-04	MK1K	Patent expired

Publication	Publication Date	Title
US5032406A (en)	1991-07-16	Dual-action tablet
RU2201754C2 (ru)	2003-04-10	Фармацевтический состав, способ его получения, способ лечения психотических состояний и гиперактивности
US5948437A (en)	1999-09-07	Pharmaceutical compositions using thiazepine
KR100517090B1 (ko)	2005-09-27	서방형 제약 조성물 및 제약 활성제의 방출 방법
RU2466717C2 (ru)	2012-11-20	Фармацевтический твердый препарат, содержащий бензоазепины, и способ его получения
NO173317B (no)	1993-08-23	Fremgangsmaate for fremstilling av et fast farmasoeytisk preparat med forsinket frigjoering
NO340960B1 (no)	2017-07-31	Modifiserte frigivende tamsulosintabletter
NO331689B1 (no)	2012-02-27	Oral farmasoytisk sammensetning omfattende rivastigmin, samt anvendelse av rivastigmin
US20110257239A1 (en)	2011-10-20	Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent
US6333361B1 (en)	2001-12-25	Pharmaceutical composition containing zafirlukast
US20040127541A1 (en)	2004-07-01	Bicifadine formulation
WO2004032904A1 (en)	2004-04-22	Controlled release pharmaceutical compositions containing sodium alginate and sodium calcium alginate
US20040228918A1 (en)	2004-11-18	Granule modulating hydrogel system
JP3815705B2 (ja)	2006-08-30	固形薬剤及びその製造方法